Skip to main content
. 2019 May 7;8(5):e11448. doi: 10.2196/11448

Table 3.

Common features and differences between phase 1 and phase 2.

Issues Phase 1 Phase 2
Evaluation focus Drugs and adverse events entity recognition Adverse drug reaction relationships recognition
Gold standard (manual annotations) Not blind Blind
Gold standard annotators Pharmacovigilance experts Experts in medical terminologies
Interannotator agreement No Yes
Granularity issue No Yes
Sentence boundary issue No Yes